SEP 1 2 2005

FAX TRANSMISSION September 12, 2005 DATE: 10/733,621-Conf. #8531 **Application Number** PTO IDENTIFIER: **Patent Number** Atul Varadhachary et al. inventor: US Patent and Trademark Office MESSAGE TO: (571) 273-8300 FAX NUMBER: FULBRIGHT & JAWORSKI L.L.P. FROM: Melissa W. Acosta, Ph.D. (10315951) (01768) PHONE: (713) 651-5407 Attorney Dkt. #: HO-P02705US2 (Agennix) PAGES (Including Cover Sheet): Amendment After Final Action Dated 7-11-05 (37 C.F.R. Section 1.116) (7 pages) CONTENTS: Certificate of Transmission (1 page) If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (713) 651-5407 and send the original transmission to us by return mail at the address below. This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited. FULBRIGHT & JAWORSKI L.L.P. Fulbright Tower, 1301 McKinney, Suite 5100, Houston, Texas 77010-3095 Telephone: (713) 651-5151 Facalmile: (713) 651-5246

Docket No.: HO-P02705US2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Atul Varadhachary et al.

Application No.: 10/733,621

Confirmation No.: 8531

Filed: December 11, 2003

Art Unit: 1656

For: LACTOFERRIN IN THE REDUCTION OF

Examiner: C. M. Kam

PAIN

AMENDMENT AFTER FINAL ACTION (37 C.F.R. SECTION 1.116)

MS AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated July 11, 2005, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2of this paper.

Remarks/Arguments begin on page 5 of this paper.